18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy

Journal of Nuclear Medicine

Volumn 54, Issue 9, 2013, Pages 1528-1534

  Usmanij, Edwin A ^a   De Geus Oei, Lioe Fee ^a   Troost, Esther G C ^a   Peters Bax, Liesbeth ^a   Van Der Heijden, Erik H F M ^a   Kaanders, Johannes H A M ^a   Oyen, Wim J G ^a   Schuurbiers, Olga C J ^a   Bussink, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Concomitant radiotherapy chemotherapy; Early response prediction; Non small cell lung cancer; Standardized uptake value; Total lesion glycolysis

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; LUNG NON SMALL CELL CANCER; MALE; METABOLIC TUMOR VOLUME; MULTIPLE CYCLE TREATMENT; ONCOLOGICAL PARAMETERS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOLOGICAL PARAMETERS; STANDARDIZED UPTAKE VALUE; SURVIVAL TIME; TOTAL LESION GLYCOLYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; 18F-FDG PET; CLINICAL TRIAL; CONCOMITANT RADIOTHERAPY CHEMOTHERAPY; EARLY DIAGNOSIS; EARLY RESPONSE PREDICTION; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; NON-SMALL CELL LUNG CANCER; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

18F-FDG PET; CONCOMITANT RADIOTHERAPY CHEMOTHERAPY; EARLY RESPONSE PREDICTION; NON-SMALL CELL LUNG CANCER; STANDARDIZED UPTAKE VALUE; TOTAL LESION GLYCOLYSIS;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; EARLY DETECTION OF CANCER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84887334596     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.116921     Document Type: Article

References (33)

1. El-Sharouni SY, Kal HB, Battermann JJ, Schramel FM. Sequential versus concurrent chemo-radiotherapy in inoperable stage III non-small cell lung cancer. Anticancer Res. 2006;26:495-505.
2. Govindan R, Bogart J, Vokes EE. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol. 2008;3:917-928.
3. Aupérin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181-2190.
4. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379-386.
5. van Baardwijk A, Reymen B, Wanders S, et al. Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer. Eur J Cancer. 2012;48:2339-2346.
6. Machtay M, Bae K, Movsas B, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced nonsmall cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012;82:425-434.
7. Bussink J, Kaanders JH, van der Graaf WT, Oyen WJ. PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol. 2011;8:233-242.
8. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
9. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50:122S-150S.
10. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;21:1285-1292.
11. Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol. 2003;16:1102-1108.
12. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654-1664.
13. Lee DH, Kim SK, Lee HY, et al. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic nonsmall cell lung cancer. J Thorac Oncol. 2009;4:816-821.
14. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol. 1998;9:1193-1198.
15. Nahmias C, Hanna WT, Wahl LM, Long MJ, Hubner KF, Townsend DW. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med. 2007;48:744-751.
16. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in nonsmall- cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657.
17. van Baardwijk A, Bosmans G, Dekker A, et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy: a prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol. 2007;82:145-152.
18. de Geus-Oei LF, van der Heijden HF, Visser EP, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med. 2007;48:1592-1598.
19. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging-version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200.
20. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung Cancer. Radiology. 2012;264:559-566.
21. Zhang H, Wroblewski K, Liao S, et al. Prognostic value of metabolic tumor burden from 18F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol. 2013;20:32-40.
22. Liao S, Penney BC, Wroblewski K, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:27-38.
23. Patz EF Jr, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR. 2000;174: 769-774.
24. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5:429-441.
25. Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012;18:5585-5594.
26. Meijer TW, Schuurbiers OC, Kaanders JH, et al. Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4. Lung Cancer. 2012;76: 316-323.
27. Yohena T, Yoshino I, Takenaka T, et al. Upregulation of hypoxia-inducible factor-1alpha mRNA and its clinical significance in non-small cell lung cancer. J Thorac Oncol. 2009;4:284-290.
28. Kong FM, Frey KA, Quint LE, et al. A pilot study of [18F] fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol. 2007;25:3116-3123.
29. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
30. Huang W, Zhou T, Ma L, et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:1628-1635.
31. Massaccesi M, Calcagni ML, Spitilli MG, et al. 18 F-FDG PET-CT during chemoradiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose. Radiat Oncol. 2012;7:106.
32. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-171.
33. De Ruysscher D, van Baardwijk A, Steevens J, et al. Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved longterm survival of patients with stage III NSCLC: a prospective population-based study. Radiother Oncol. 2012;102:228-233.